342 related articles for article (PubMed ID: 30747554)
41. High-Throughput Cytochrome P450 Cocktail Inhibition Assay for Assessing Drug-Drug and Drug-Botanical Interactions.
Li G; Huang K; Nikolic D; van Breemen RB
Drug Metab Dispos; 2015 Nov; 43(11):1670-8. PubMed ID: 26285764
[TBL] [Abstract][Full Text] [Related]
42. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
[TBL] [Abstract][Full Text] [Related]
43. A sensitive and specific CYP cocktail assay for the simultaneous assessment of human cytochrome P450 activities in primary cultures of human hepatocytes using LC-MS/MS.
Pillai VC; Strom SC; Caritis SN; Venkataramanan R
J Pharm Biomed Anal; 2013 Feb; 74():126-32. PubMed ID: 23245243
[TBL] [Abstract][Full Text] [Related]
44. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.
Ko JW; Desta Z; Soukhova NV; Tracy T; Flockhart DA
Br J Clin Pharmacol; 2000 Apr; 49(4):343-51. PubMed ID: 10759690
[TBL] [Abstract][Full Text] [Related]
45. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
46. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA.
Jacobson PA; Green K; Birnbaum A; Remmel RP
Cancer Chemother Pharmacol; 2002 Jun; 49(6):461-7. PubMed ID: 12107550
[TBL] [Abstract][Full Text] [Related]
47. Involvement of CYP3A4/5 and CYP2D6 in the metabolism of aconitine using human liver microsomes and recombinant CYP450 enzymes.
Tang L; Ye L; Lv C; Zheng Z; Gong Y; Liu Z
Toxicol Lett; 2011 Apr; 202(1):47-54. PubMed ID: 21277363
[TBL] [Abstract][Full Text] [Related]
48. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
[TBL] [Abstract][Full Text] [Related]
49. Development of GC-MS based cytochrome P450 assay for the investigation of multi-herb interaction.
Oh HA; Lee H; Kim D; Jung BH
Anal Biochem; 2017 Feb; 519():71-83. PubMed ID: 28007398
[TBL] [Abstract][Full Text] [Related]
50. Inhibitory effects of the main metabolites of Apatinib on CYP450 isozymes in human and rat liver microsomes.
Pang NH; Xu RA; Chen LG; Chen Z; Hu GX; Zhang BW
Toxicol In Vitro; 2024 Mar; 95():105739. PubMed ID: 38042355
[TBL] [Abstract][Full Text] [Related]
51. Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay.
Turpeinen M; Uusitalo J; Jalonen J; Pelkonen O
Eur J Pharm Sci; 2005 Jan; 24(1):123-32. PubMed ID: 15626586
[TBL] [Abstract][Full Text] [Related]
52. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1.
Kharasch ED; Hankins DC; Jubert C; Thummel KE; Taraday JK
Drug Metab Dispos; 1999 Jun; 27(6):717-23. PubMed ID: 10348802
[TBL] [Abstract][Full Text] [Related]
53. Profiling induction of cytochrome p450 enzyme activity by statins using a new liquid chromatography-tandem mass spectrometry cocktail assay in human hepatocytes.
Feidt DM; Klein K; Hofmann U; Riedmaier S; Knobeloch D; Thasler WE; Weiss TS; Schwab M; Zanger UM
Drug Metab Dispos; 2010 Sep; 38(9):1589-97. PubMed ID: 20551241
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of cytochrome P450 by ethambutol in human liver microsomes.
Lee SY; Jang H; Lee JY; Kwon KI; Oh SJ; Kim SK
Toxicol Lett; 2014 Aug; 229(1):33-40. PubMed ID: 24910189
[TBL] [Abstract][Full Text] [Related]
55. Effects of green tea catechins on cytochrome P450 2B6, 2C8, 2C19, 2D6 and 3A activities in human liver and intestinal microsomes.
Misaka S; Kawabe K; Onoue S; Werba JP; Giroli M; Tamaki S; Kan T; Kimura J; Watanabe H; Yamada S
Drug Metab Pharmacokinet; 2013; 28(3):244-9. PubMed ID: 23268924
[TBL] [Abstract][Full Text] [Related]
56.
Zhang N; Liu J; Chen Z; Dou W
Pharm Biol; 2019 Dec; 57(1):571-576. PubMed ID: 31456483
[No Abstract] [Full Text] [Related]
57. Inhibitory Mechanisms of Myricetin on Human and Rat Liver Cytochrome P450 Enzymes.
Lou D; Bao SS; Li YH; Lin QM; Yang SF; He JY
Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):611-618. PubMed ID: 30825074
[TBL] [Abstract][Full Text] [Related]
58. Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology.
Yoshitomi S; Ikemoto K; Takahashi J; Miki H; Namba M; Asahi S
Toxicol In Vitro; 2001 Jun; 15(3):245-56. PubMed ID: 11377097
[TBL] [Abstract][Full Text] [Related]
59. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ
J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717
[TBL] [Abstract][Full Text] [Related]
60. An in-vitro cocktail assay for assessing compound-mediated inhibition of six major cytochrome P450 enzymes.
Wang JJ; Guo JJ; Zhan J; Bu HZ; Lin JH
J Pharm Anal; 2014 Aug; 4(4):270-278. PubMed ID: 29403890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
